BRVE Braveheart Bio, Inc. - Common Stock
No fundamentals data yet for this ticker.
Company insiders 10 insiders · 0 officers · 0 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | Aug. 7, 2026 C | 7,420,091 | 0 | 0 | $0 |
| CHIMOVITS EREZ | — | Aug. 7, 2026 C | 273,333 | 2 | 0 | $34,920,000 |
| Tim Lohoff | — | Aug. 5, 2026 A | — | 0 | 0 | $0 |
| Michele A. Anderson | — | Aug. 5, 2026 A | 332,161 | 1 | 0 | $19,998 |
| David I Malek | — | Aug. 5, 2026 A | 533,845 | 1 | 0 | $74,988 |
| Jasper Bos | — | Aug. 5, 2026 A | — | 0 | 0 | $0 |
| Travis Murdoch | — | Aug. 5, 2026 A | 2,940,670 | 1 | 0 | $1,499,994 |
| Christopher Viehbacher | — | Aug. 5, 2026 A | 609,519 | 1 | 0 | $1,499,994 |
| James Paul Rickey | — | Aug. 5, 2026 A | 520,927 | 1 | 0 | $499,986 |
| David Charles Lubner | — | Aug. 5, 2026 A | 55,555 | 1 | 0 | $999,990 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | Aug. 18, 2026 | 17.20% | Initial filing | — | SEC |
| AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C., Marc L. Andreessen, Benjamin A. Horowitz | Aug. 14, 2026 | 11.40% | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.